CD274 and neoplasm: Biomarkers with clinical applicability encompass microsatellite instability (MSI)/mismatch repair (MMR) status, a high tumor mutational burden (TMB), along with factors associated with the tumor microenvironment, including programmed death ligand 1 (PD-L1) expression and immune-related RNA expression [5,6,7].